Pregabalin, the first of the three medications that have gained US FDA approval for fibromyalgia, is an α2 δ ligand that acts by binding the α2 δ subunit of voltage-gated calcium channels (Micó and Prieto, 2012). Here, ATXN2L is linked to fibromyalgia.